| Title: |
Real-world effectiveness of risankizumab in Crohn’s disease: a pan UK retrospective cohort study |
| Authors: |
Elford, AT; Constantine-Cooke, N; Shah, K; Faloon, SC; Manti, M; Zare, B; Colwill, M; Yeo, JH; Akbani, U; Morgan, H; Mulligan, RJ; Radia, C; Young, D; Badrulhisham, F; Morris, S; Anwar-Hashim, Z; Hassall, JHA; Thomas, M; Dyall, L; Clough, J; Mahmood, T; Mohammed, A; Mohanan, V; Brownson, E; Hancox, S; Disney, B; Verma, AM; Seenan, JP; Johnston, E; Goel, R; Hicks, LC; Sebastian, S; Hale, M; Harvey, P; Cooney, R; Ahmad, T; Cummings, F; Kent, A; King, A; Limdi, JK; Selinger, C; McCartney, S; Pollok, R; Irving, PM; Samaan, MA; Arebi, N; Parkes, G; Lees, CW; Plevris, N |
| Publisher Information: |
BMJ |
| Publication Year: |
2026 |
| Collection: |
St George's University of London: Repository |
| Description: |
Objective Risankizumab is an interleukin-23 p19 subunit inhibitor which received approval for Crohn’s disease (CD) by UK licensing authorities in May 2023. Our aim was to evaluate the real-world outcomes of risankizumab in the UK. Design We conducted a retrospective, multicentre, cohort study of patients with CD treated with risankizumab across 25 health boards in the UK between 1 January 2021 and 1 November 2024. Our primary outcome was treatment persistence at 6 months. Our secondary endpoints were steroid-free clinical remission (Harvey-Bradshaw index |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| ISSN: |
2041-4137 |
| Relation: |
https://openaccess.sgul.ac.uk/id/eprint/118266/3/flgastro-2025-103449.full.pdf; https://openaccess.sgul.ac.uk/id/eprint/118266/1/flgastro-2025-103449-inline-supplementary-material-1.pdf; https://openaccess.sgul.ac.uk/id/eprint/118266/2/flgastro-2025-103449-inline-supplementary-material-2.pdf; Elford, AT; Constantine-Cooke, N; Shah, K; Faloon, SC; Manti, M; Zare, B; Colwill, M; Yeo, JH; Akbani, U; Morgan, H; et al. Elford, AT; Constantine-Cooke, N; Shah, K; Faloon, SC; Manti, M; Zare, B; Colwill, M; Yeo, JH; Akbani, U; Morgan, H; Mulligan, RJ; Radia, C; Young, D; Badrulhisham, F; Morris, S; Anwar-Hashim, Z; Hassall, JHA; Thomas, M; Dyall, L; Clough, J; Mahmood, T; Mohammed, A; Mohanan, V; Brownson, E; Hancox, S; Disney, B; Verma, AM; Seenan, JP; Johnston, E; Goel, R; Hicks, LC; Sebastian, S; Hale, M; Harvey, P; Cooney, R; Ahmad, T; Cummings, F; Kent, A; King, A; Limdi, JK; Selinger, C; McCartney, S; Pollok, R; Irving, PM; Samaan, MA; Arebi, N; Parkes, G; Lees, CW; Plevris, N (2026) Real-world effectiveness of risankizumab in Crohn’s disease: a pan UK retrospective cohort study. Frontline Gastroenterology. ISSN 2041-4137 https://doi.org/10.1136/flgastro-2025-103449 SGUL Authors: Pollok, Richard Charles G |
| DOI: |
10.1136/flgastro-2025-103449 |
| Availability: |
https://openaccess.sgul.ac.uk/id/eprint/118266/; https://doi.org/10.1136/flgastro-2025-103449 |
| Rights: |
cc_by_4 |
| Accession Number: |
edsbas.A42DD751 |
| Database: |
BASE |